Core Viewpoint - Adaptive Biotechnologies Corporation (NASDAQ:ADPT) is experiencing positive momentum with multiple analysts upgrading their price targets following a strong Q4 earnings report, highlighting its growth potential in the specialty labs sector. Group 1: Analyst Upgrades - TD Cowen upgraded the price target for Adaptive Biotechnologies from $20 to $21 while maintaining a Buy rating, citing factors such as community adoption and a shift to blood-based testing as key drivers [1] - BTIG maintained a Buy rating and increased the price target from $21 to $22, describing the company as a leading growth story in specialty labs [2] - JPMorgan raised the price objective from $20 to $21 while retaining an Overweight rating, noting strong Q4 results and projecting FY26 MRD business revenue between $255 million and $265 million [3] Group 2: Company Overview - Adaptive Biotechnologies develops an immune medicine platform, offering products such as immunoSEQ, clonoSEQ, cellular treatment, and vaccinations [5]